glp-1 factory Peptide Expansion Investment of €900m GLP-1 Contract Manufacturing Driving CDMO

GLP-1 medications carry a prescribing warning regarding medullary thyroid carcinoma risk observed in rodent studies - a finding whose clinical significance in humans at therapeutic doses continues to be monitored in post-market surveillance

The ATTAIN program encompasses multiple Phase 3 trials in obesity (ATTAIN-1, ATTAIN-2, ATTAIN-3, ATTAIN-MAINTAIN), while the ACHIEVE program covers type 2 diabetes indications (ACHIEVE-1 through ACHIEVE-5, plus regional studies)

Health threats resulting from the explosion of counterfeit drugs are well documented [Reference Blumenberg, Hughes, Reckers, Ellison and Gerona15] and fueled in part by illegitimate access through the internet [Reference Michael White16]

J., 1 (3), 26-45

instead, they can resensitize insulin signaling